
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Free Report) – Analysts at Brookline Capital Markets reduced their FY2026 earnings estimates for shares of Perspective Therapeutics in a research note issued to investors on Tuesday, November 10th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will earn ($1.00) per share for the year, down from their prior estimate of ($0.99). The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($1.01) per share. Brookline Capital Markets also issued estimates for Perspective Therapeutics’ Q4 2026 earnings at ($0.25) EPS.
A number of other research firms also recently issued reports on CATX. Piper Sandler decreased their price objective on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Wedbush reissued an “outperform” rating and issued a $7.00 target price (down from $9.00) on shares of Perspective Therapeutics in a research report on Tuesday. BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a research note on Monday, October 26th. William Blair assumed coverage on Perspective Therapeutics in a research report on Friday, September 18th. They set an “outperform” rating for the company. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a research note on Friday, October 30th. Nine analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.10.
Perspective Therapeutics Price Performance
Shares of Perspective Therapeutics stock opened at $0.94 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.61 and a current ratio of 5.18. The stock’s 50-day moving average is $2.11 and its 200-day moving average is $3.44. Perspective Therapeutics has a one year low of $0.78 and a one year high of $6.16.
Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. Perspective Therapeutics had a negative return on equity of 42.25% and a negative net margin of 55,866.82%.
Hedge Funds Weigh In On Perspective Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Provenance Wealth Advisors LLC acquired a new stake in shares of Perspective Therapeutics during the 3rd quarter worth about $44,000. Auctus Advisors LLC grew its stake in Perspective Therapeutics by 83.6% in the 3rd quarter. Auctus Advisors LLC now owns 37,359 shares of the company’s stock valued at $103,000 after buying an additional 17,015 shares during the last quarter. Taylor & Morgan Wealth Management LLC grew its stake in Perspective Therapeutics by 30.3% in the 3rd quarter. Taylor & Morgan Wealth Management LLC now owns 86,000 shares of the company’s stock valued at $236,000 after buying an additional 20,000 shares during the last quarter. Russell Investments Group Ltd. grew its stake in Perspective Therapeutics by 53.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company’s stock valued at $168,000 after buying an additional 21,150 shares during the last quarter. Finally, Quantinno Capital Management LP bought a new position in Perspective Therapeutics in the 1st quarter valued at about $273,000. 54.66% of the stock is owned by institutional investors.
Insider Buying and Selling
In related news, CEO Johan M. Spoor acquired 47,000 shares of the company’s stock in a transaction dated Wednesday, November 11th. The shares were bought at an average price of $0.81 per share, for a total transaction of $38,070.00. Following the purchase, the chief executive officer directly owned 106,383 shares in the company, valued at approximately $86,170.23. This trade represents a 79.15% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Markus Puhlmann acquired 35,000 shares of the company’s stock in a transaction dated Thursday, November 12th. The shares were bought at an average price of $0.84 per share, for a total transaction of $29,400.00. Following the purchase, the insider owned 178,542 shares in the company, valued at approximately $149,975.28. This represents a 24.38% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders acquired 88,000 shares of company stock valued at $72,450. Corporate insiders own 2.99% of the company’s stock.
Trending Headlines about Perspective Therapeutics
These are some of the CATX headlines that stood out recently:
- Positive Sentiment: CEO Johan Spoor bought 47,000 shares at an average price of $0.81, increasing his holdings by 79%. Insider Markus Puhlmann also bought 41,000 shares across two transactions at average prices of $0.83 and $0.84. These open-market purchases may signal insiders’ confidence in the company. Insider purchase report
- Positive Sentiment: BMO Capital gave CATX a Buy rating, adding a bullish analyst view. BMO Capital rating
- Neutral Sentiment: Brookline Capital Markets made slightly different revisions to its earnings forecasts: it raised its Q4 2026 estimate to a loss of $0.25 per share from $0.26, but lowered its full-year estimate to a loss of $1.00 from $0.99. Perspective Therapeutics analyst estimates
About Perspective Therapeutics
Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.
Featured Articles
- Five stocks we like better than Perspective Therapeutics
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
